The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, reports the findings of Alliance A061202 (NCT02004275), a Phase I/II study comparing the safety and efficacy of pomalidomide, dexamethasone and ixazomib (IXA-POM-DEX) versus pomalidomide and dexamethasone (POM-DEX) in lenalidomide-refractory patients with multiple myeloma. Dr Richardson first outlines the study design and explains that patients treated with the IXA-POM-DEX triplet had a significantly higher progression-free survival (PFS). In addition, Dr Richardson explains that this all-oral combination was well-tolerated and there was no COVID-19-related mortality. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
